대학병원의 Formulary로 선정되어 사용 중인 원내 퀴놀론 주사제의 약물사용에 대한 평가

Evaluation of Inpatient Use for IV Quinolones in an University Hospital Formulary

  • 김훈희 (충북대학교 약학대학 임상약학실) ;
  • 이옥상 (충북대학교 약학대학 임상약학실) ;
  • 정선회 (충북대학교 약학대학 임상약학실) ;
  • 임성실 (충북대학교 약학대학 임상약학실)
  • Kim, Hoon-Hee (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Lee, Ok-Sang (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Jung, Sun-Hoi (Clinical Pharmacy, College of Pharmacy, Chungbuk National University) ;
  • Lim, Sung-Cil (Clinical Pharmacy, College of Pharmacy, Chungbuk National University)
  • 투고 : 2011.11.15
  • 심사 : 2012.03.19
  • 발행 : 2012.03.31

초록

The quinolones are broad-spectrum antibiotics and enhanced antimicrobial activity has extended the use of the quinolones beyond the traditional indications for quinolone antibiotics in the treatment of urinary tract infections. The quinolones are effective in a wider variety of infectious diseases, including skin and respiratory infections. Because of their excellent safety and tolerability, they have become popular alternatives to penicillin and cephalosporin derivatives in the treatment of various infections. A retrospective study was performed to evaluate efficacy and safety of IV quinolones for inpatient use. Total 117 patients who administerd quinolones for longer than 3 continuous days at community hospital from October 1st, 2008 to December 31st, 2008 were reviewed. The criterias for drug evaluation were included the validation of indication, outcome, dosage and side effects. In the results, ciprofloxacin 13 (total 93), levofloxacin 3 (total 59) and moxifloxacin 2 (total 19) cases were not met the criterias based on the culture results. Major indications were pneumonia (ciprofloxacin 16.3%, levofloxacin 67.8%, moxifloxacin 84.2%), urinary tract infection (ciprofloxacin 44.1%), skin infection (ciprofloxacin 7.5%, levofloxacin 20.3%, moxifloxacin 10.5%), intra-abdominal infection (ciprofloxacin 10.8%, moxifloxacin 5.3%), etc.. In the results of quinolone monotherapy, the frequencies were each ciprofloxacin 74.2%, levofloxacin 50.8% and moxifloxacin 47.4%. In the results of dosage validation, the validities were each ciprofloxacin 54.8%, levofloxacin 94.9% and moxifloxacin 100.0%. In the results of duration validation, the validities were each ciprofloxacin 59.1%, levofloxacin 78.0% and moxifloxacin 89.5%. Adverse drug reactions were reported for total 49 cases and those were gastrointestinal tract effects including nausea, vomiting, diarrhea and central nervous system effects including headache, dizziness. In summary, the quinolones appropriately used for hospitalized patients based on this study. A focused approach emphasizing "correct use of quinolones" may reduce development of antimicrobial resistance and maximize class efficacy. Consequently, correct use of antibiotics will contribute to decrease medical expenses for person and community.

키워드

참고문헌

  1. Tillotson, g. s. Quinolones: Structure-activity Relationship and Future Predictions, Journal of Medical Biology 1996; 44: 320-4.
  2. Joseph M. Blondeau. A Review of the Comparative invitro Activities of 12 Antimicrobial Agents, with a Focus on Five New Respiratory Quinolones, Journal of Antimicribial Chemotherapy 1999; 43: 1-11.
  3. Ppin J, Saheb N, Coulombe MA, et al., J . Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-associated Diarrhea: a Cohort Study during an Epidemic in Quebec, Clinical Infectious Diseases 2005; 41(9): 1254-60. https://doi.org/10.1086/496986
  4. Robert P. Fluoroquinolone Positioning in Hospital Antimicrobial Stepwadrship Programs, Pharmacists' online information resource 2007; 32: 12
  5. Rosemary R. Berardi, Pharm D, FCCP, FASHP Professor of Pharmacy, Department of Clinical Science, The University of Michigan Colledge of Pharmacy, Ann Arbor Handbook of Nonprescription Drugs - an interactive approach to selfcare 14th edition. 2006; American Pharmacists Association.
  6. 홍주형, 유지숙, 이길호. Ciprofloxacin 약제에 내성을 보이는 대장균에 의한 소아요로감염: 위험 인자 분석 Korean Journal of Urology 2009; 50(12): 1219-1224. https://doi.org/10.4111/kju.2009.50.12.1219
  7. Judith A, Aberg, Morton P. Goldman, Larry D. Gray, Jennifer K. Long(2006), Infectious Diseases Handbook, 6th Edition, Ohio, Lexi-Comp, Inc.
  8. Carrie, Ag; Kozyrskyj, Al. Outpatient Treatment of Community-acquired Pneumonia: Evolving Trends and a Focus on Fluoroquinolones. (PDF), The Canadian Journal of Clinical Pharmacology 2006; 13(1): e102-11.
  9. Jacobs M. Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.
  10. Lescher, G. Y., Forelich, E. D., Gruet, M. D., Bailey, H. J. and Brundage, R. P. 1, 8-Naphthyridine Derivatives: a New Class of Chemotherapeutic Agents, Journal of Medical Phamaceutical Chemistry 1962; 5: 1063-8. https://doi.org/10.1021/jm01240a021
  11. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone Prescribing in the United States: 1995 to 2002, The American Journal of Medicine 2005; 118(3): 259-68. https://doi.org/10.1016/j.amjmed.2004.09.015
  12. Liu, H.; Mulholland, SG. Appropriate Antibiotic Treatment of Genitourinary Infections in Hospitalized Patients. The American Journal of Medicine 2005; 118 Suppl 7A: 14S-20S.
  13. MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. Antimicrobial Drug Prescribing for Pneumonia in Ambulatory Care, Emerging Infectious Diseases 2005; 11 (3): 380-4. https://doi.org/10.3201/eid1103.040819
  14. Marrie TJ, Lau CY, Wheeler SL, A Controlled Trial of a Critical Pathway for Treatment of Community-acquired Pneumonia, Journal of the American Medical Association 2000; 283: 749-755. https://doi.org/10.1001/jama.283.6.749
  15. Marrie TJ. Experience with Levofloxacin in a Critical Pathway for the Treatment of Community-acquired Pneumonia,Chemotherapy. 2004; 50(suppl 1): 11-15.
  16. Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. Fluoroquinolone-resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: a Public Health Success Story. (PDF), Clinical Infectious Diseases 2007; 44(7): 977-80. https://doi.org/10.1086/512369
  17. Robicsek A, Jacoby GA, Hooper DC. The Worldwide Emergence of Plasmid-mediated Quinolone Resistance, Lancet Infectious Disease 2006; 6(10): 629-40. https://doi.org/10.1016/S1473-3099(06)70599-0